Project Name：Posaconazole
Registration Classification：3+6
Formulations and specifications ：Oral suspension, 40mg/ml
Indications：For the prevention of invasive aspergillosis and Candida infections, also for the treatment of oropharyngeal candidiasis and fluconazole and itraconazole -resistant oropharyngeal candidiasis,patients older than 13 years only .
Original Research Company：Schering-Plough
Progress ：Pharmaceutical Research in progress
Category：Anti-infectives
